{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:54:01Z","timestamp":1791899641327,"version":"4.3.4"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":265,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Accurate molecular characterization of gliomas is essential for determining prognosis and guiding therapeutic decisions. In recent years, liquid biopsy for analysis of circulating tumor DNA (ctDNA) in blood or cerebrospinal fluid (CSF) has emerged as a promising, minimally invasive alternative. This study evaluates the existing literature on the utility of ctDNA detection in CSF and blood in patients with gliomas, with the goal of assessing its ability to identify mutations concordant with those detected in tumor tissue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted up to April 30, 2026, to identify cohorts that evaluated the effectiveness of ctDNA-based liquid biopsies for gliomas. The primary assessed outcomes were the sensitivity and specificity of the liquid biopsies using CSF or plasma. A pooled sensitivity analysis was performed, as well as summary receiver operating characteristic (SROC) curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-eight studies met the inclusion criteria, encompassing 613 patients. Meta-analysis of diagnostic performance revealed improved biomarker performance for CSF (Area under the curve [AUC] 0.95) ctDNA. Pooled sensitivity for ctDNA detection in patients with gliomas was higher in CSF 0.79 (95% CI, 0.69-0.85) than in plasma 0.29 (95% CI, 0.15-0.47), P\u2009&amp;lt;\u2009.0001.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The literature demonstrates a promising performance of ctDNA analysis in patients with diffuse gliomas as a liquid biopsy strategy. CSF ctDNA analysis exhibited superior sensitivity compared to plasma ctDNA. This meta-analysis supports the utility of ctDNA, particularly CSF ctDNA, as a complementary diagnostic tool in neuro-oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag253","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:37:09Z","timestamp":1790077029000},"source":"Crossref","is-referenced-by-count":0,"title":["Circulating tumor DNA as a liquid biopsy for glioma detection in cerebrospinal fluid and plasma: A systematic review and meta-analysis"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5491-2502","authenticated-orcid":false,"given":"Christian","family":"Amezquita-Contreras","sequence":"first","affiliation":[{"name":"Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Bueno","sequence":"additional","affiliation":[{"name":"Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Arellano","sequence":"additional","affiliation":[{"name":"Houston Methodist Hospital , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Ruvalcaba-Guerrero","sequence":"additional","affiliation":[{"name":"Houston Research Institute , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E","family":"Johnson","sequence":"additional","affiliation":[{"name":"Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8041-8399","authenticated-orcid":false,"given":"Antonio","family":"Dono","sequence":"additional","affiliation":[{"name":"Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9757-1453","authenticated-orcid":false,"given":"Yoshua","family":"Esquenazi","sequence":"additional","affiliation":[{"name":"Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6854-6830","authenticated-orcid":false,"given":"Leomar Y","family":"Ballester","sequence":"additional","affiliation":[{"name":"Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center , Houston, Texas,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"2026101309215473900_vdag253-B1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox192","article-title":"Molecular subtyping of tumors from patients with familial glioma","volume":"20","author":"Ruiz","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026101309215473900_vdag253-B2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"2026101309215473900_vdag253-B3","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026101309215473900_vdag253-B4","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/cancers16051009","article-title":"Liquid biopsy for glioma using cell-free DNA in cerebrospinal fluid","volume":"16","author":"Otsuji","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026101309215473900_vdag253-B5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11060-024-04695-2","article-title":"Establishing the utility of multi-platform liquid biopsy by integrating the CSF methylome and proteome in CNS tumours","volume":"169","author":"Landry","year":"2024","journal-title":"J Neurooncol"},{"key":"2026101309215473900_vdag253-B6","doi-asserted-by":"publisher","first-page":"22477","DOI":"10.1038\/srep22477","article-title":"Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma","volume":"6","author":"Parker","year":"2016","journal-title":"Sci Rep"},{"key":"2026101309215473900_vdag253-B7","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1158\/1078-0432.CCR-22-2903","article-title":"Liquid biopsy of cerebrospinal fluid enables selective profiling of glioma molecular subtypes at first clinical presentation","volume":"29","author":"Orzan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026101309215473900_vdag253-B8","doi-asserted-by":"publisher","first-page":"112007","DOI":"10.1016\/j.jocn.2026.112007","article-title":"Butterfly glioblastoma: genetic alterations and outcomes","volume":"149","author":"Amezquita-Contreras","year":"2026","journal-title":"J Clin Neurosci"},{"key":"2026101309215473900_vdag253-B9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026101309215473900_vdag253-B10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026101309215473900_vdag253-B11","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026101309215473900_vdag253-B12","doi-asserted-by":"publisher","first-page":"k4597","DOI":"10.1136\/bmj.k4597","article-title":"A guide to systematic review and meta-analysis of prognostic factor studies","volume":"364","author":"Riley","year":"2019","journal-title":"BMJ"},{"key":"2026101309215473900_vdag253-B13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s44199-023-00054-8","article-title":"Continuity corrected Wilson interval for the difference of two independent proportions","volume":"22","author":"Shan","year":"2023","journal-title":"J Stat Theory Appl"},{"key":"2026101309215473900_vdag253-B14","article-title":"Modern Epidemiology","author":"Rothman","year":"2008"},{"key":"2026101309215473900_vdag253-B15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12874-016-0196-1","article-title":"Modelling multiple thresholds in meta-analysis of diagnostic test accuracy studies","volume":"16","author":"Steinhauser","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"2026101309215473900_vdag253-B16","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Nat Commun"},{"key":"2026101309215473900_vdag253-B17","doi-asserted-by":"publisher","first-page":"5282","DOI":"10.1158\/1078-0432.CCR-17-3717","article-title":"TERT promoter mutation detection in cell-free tumor-derived DNA in patients with IDH wild-type glioblastomas: a pilot prospective study","volume":"24","author":"Juratli","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026101309215473900_vdag253-B18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00401-018-1936-6","article-title":"Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA","volume":"137","author":"Pan","year":"2019","journal-title":"Acta Neuropathol"},{"key":"2026101309215473900_vdag253-B19","doi-asserted-by":"publisher","first-page":"101411","DOI":"10.1016\/j.mcp.2019.06.001","article-title":"Assessment of ctDNA in CSF may be a more rapid means of assessing surgical outcomes than plasma ctDNA in glioblastoma","volume":"46","author":"Li","year":"2019","journal-title":"Mol Cell Probes"},{"key":"2026101309215473900_vdag253-B20","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.annonc.2025.02.005","article-title":"ctDNA detection in cerebrospinal fluid and plasma and mutational concordance with the primary tumor in a multicenter prospective study of patients with glioma","volume":"36","author":"Cabezas-Camarero","year":"2025","journal-title":"Ann Oncol"},{"key":"2026101309215473900_vdag253-B21","doi-asserted-by":"publisher","first-page":"vdaf270","DOI":"10.1093\/noajnl\/vdaf270","article-title":"Targeted next-generation sequencing-based sequencing of cell-free DNA in cerebrospinal fluid uncovers cancer-specific mutations in patients with brain cancer using a widely available panel","volume":"8","author":"K\u00f6pp","year":"2026","journal-title":"Neurooncol Adv"},{"key":"2026101309215473900_vdag253-B22","doi-asserted-by":"publisher","first-page":"9704","DOI":"10.1073\/pnas.1511694112","article-title":"Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord","volume":"112","author":"Wang","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101309215473900_vdag253-B23","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1200\/JCO.2016.66.6487","article-title":"Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid","volume":"34","author":"Pentsova","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026101309215473900_vdag253-B24","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1158\/1078-0432.CCR-17-3800","article-title":"Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumor DNA from cerebrospinal fluid","volume":"24","author":"Mart\u00ednez-Ricarte","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026101309215473900_vdag253-B25","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809323","article-title":"Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients","volume":"10","author":"Mouliere","year":"2018","journal-title":"EMBO Mol Med"},{"key":"2026101309215473900_vdag253-B26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","article-title":"Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid","volume":"565","author":"Miller","year":"2019","journal-title":"Nature"},{"key":"2026101309215473900_vdag253-B27","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/CM9.0000000000000843","article-title":"Assessment of circulating tumor DNA in cerebrospinal fluid by whole exome sequencing to detect genomic alterations of glioblastoma","volume":"133","author":"Duan","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"2026101309215473900_vdag253-B28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/jjco\/hyz156","article-title":"Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas","volume":"50","author":"Zhao","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"2026101309215473900_vdag253-B29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11060-020-03682-7","article-title":"Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid","volume":"152","author":"Fujioka","year":"2021","journal-title":"J Neurooncol"},{"key":"2026101309215473900_vdag253-B30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1182\/blood.2020010137","article-title":"A rapid genotyping panel for detection of primary central nervous system lymphoma","volume":"138","author":"Gupta","year":"2021","journal-title":"Blood"},{"key":"2026101309215473900_vdag253-B31","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11040681","article-title":"Low detection rate of H3K27M mutations in cerebrospinal fluid obtained from lumbar puncture in newly diagnosed diffuse midline gliomas","volume":"11","author":"On","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2026101309215473900_vdag253-B32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11060-022-04060-1","article-title":"IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas","volume":"159","author":"Fujita","year":"2022","journal-title":"J Neurooncol"},{"key":"2026101309215473900_vdag253-B33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s40478-024-01846-4","article-title":"Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors","volume":"12","author":"Hickman","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"2026101309215473900_vdag253-B34","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1158\/1078-0432.CCR-23-2907","article-title":"Cerebrospinal fluid cfDNA sequencing for classification of central nervous system glioma","volume":"30","author":"Iser","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026101309215473900_vdag253-B35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12031-025-02361-4","article-title":"Cerebrospinal fluid-derived genomic alterations tracking glioma","volume":"75","author":"Zhu","year":"2025","journal-title":"J Mol Neurosci"},{"key":"2026101309215473900_vdag253-B36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18020256","article-title":"Analytical validation and clinical sensitivity of the belay SummitTM 2.0 cerebrospinal fluid liquid biopsy test-an expanded comprehensive genomic profiling platform for central nervous system malignancies","volume":"18","author":"Khurana","year":"2026","journal-title":"Cancers (Basel)"},{"key":"2026101309215473900_vdag253-B37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/neuonc\/nop041","article-title":"Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades","volume":"12","author":"Lavon","year":"2010","journal-title":"Neuro Oncol"},{"key":"2026101309215473900_vdag253-B38","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1212\/WNL.0b013e31826e9b0a","article-title":"Detection of IDH1 mutation in the plasma of patients with glioma","volume":"79","author":"Boisselier","year":"2012","journal-title":"Neurology"},{"key":"2026101309215473900_vdag253-B39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11060-013-1209-0","article-title":"Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients","volume":"115","author":"Salkeni","year":"2013","journal-title":"J Neurooncol"},{"key":"2026101309215473900_vdag253-B40","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026101309215473900_vdag253-B41","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1016\/j.wneu.2019.01.092","article-title":"Examination of plasma cell-free DNA of glioma patients by whole exome sequencing","volume":"125","author":"Sun","year":"2019","journal-title":"World Neurosurg."},{"key":"2026101309215473900_vdag253-B42","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1158\/1078-0432.CCR-19-2533","article-title":"Clinical utility of plasma cell-free DNA in adult patients with newly diagnosed glioblastoma: a pilot prospective study","volume":"26","author":"Bagley","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026101309215473900_vdag253-B43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/ijc.IJC_551_17","article-title":"Cell-free circulating tumor DNA in patients with high-grade glioma as diagnostic biomarker\u2014a guide to future directive","volume":"56","author":"Ahmed","year":"2019","journal-title":"Indian J Cancer"},{"key":"2026101309215473900_vdag253-B44","doi-asserted-by":"publisher","first-page":"CNS34","DOI":"10.2217\/cns-2018-0015","article-title":"Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain\u00a0tumors","volume":"8","author":"Piccioni","year":"2019","journal-title":"CNS Oncol"},{"key":"2026101309215473900_vdag253-B45","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1007\/s10571-023-01406-9","article-title":"Liquid biopsy in low-grade glioma: a systematic review and a proposal for a clinical utility score","volume":"43","author":"Zanin","year":"2023","journal-title":"Cell Mol Neurobiol"},{"key":"2026101309215473900_vdag253-B46","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.3390\/ijms25084221","article-title":"Diagnostic and prognostic value of circulating DNA fragments in glioblastoma multiforme patients","volume":"25","author":"Jarmuzek","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026101309215473900_vdag253-B47","doi-asserted-by":"publisher","first-page":"9707","DOI":"10.18632\/oncotarget.7110","article-title":"Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay","volume":"7","author":"Schwaederle","year":"2016","journal-title":"Oncotarget"},{"key":"2026101309215473900_vdag253-B48","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s12031-011-9617-0","article-title":"Prognostic value of free DNA quantification in serum and cerebrospinal fluid in glioma patients","volume":"46","author":"Shi","year":"2012","journal-title":"J Mol Neurosci"},{"key":"2026101309215473900_vdag253-B49","doi-asserted-by":"publisher","first-page":"544680","DOI":"10.3389\/fneur.2020.544680","article-title":"Genomic profiling of circulating tumor DNA from cerebrospinal fluid to guide clinical decision making for patients with primary and metastatic brain tumors","volume":"11","author":"Ramkissoon","year":"2020","journal-title":"Front Neurol"},{"key":"2026101309215473900_vdag253-B50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fcell.2020.00045","article-title":"Beyond the blood: CSF-Derived cfDNA for diagnosis and characterization of CNS tumors","volume":"8","author":"McEwen","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2026101309215473900_vdag253-B51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41571-022-00623-3","article-title":"Author correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"19","author":"Weller","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026101309215473900_vdag253-B52","doi-asserted-by":"publisher","first-page":"e00446","DOI":"10.1016\/j.plabm.2024.e00446","article-title":"Liquid biopsy in cancer management: integrating diagnostics and clinical applications","volume":"43","author":"Pandey","year":"2025","journal-title":"Pract Lab Med"},{"key":"2026101309215473900_vdag253-B53","doi-asserted-by":"publisher","first-page":"5364","DOI":"10.3390\/cancers13215364","article-title":"Liquid biopsy to detect minimal residual disease: methodology and impact","volume":"13","author":"Honor\u00e9","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026101309215473900_vdag253-B54","doi-asserted-by":"publisher","first-page":"1164517","DOI":"10.3389\/fonc.2023.1164517","article-title":"Liquid biopsy in hematological malignancies: current and future applications","volume":"13","author":"Talotta","year":"2023","journal-title":"Front Oncol"},{"key":"2026101309215473900_vdag253-B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.074","article-title":"Exosome-based liquid biopsies in cancer: opportunities and challenges","volume":"32","author":"Yu","year":"2021","journal-title":"Ann Oncol"},{"key":"2026101309215473900_vdag253-B56","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3892\/ol.2024.14681","article-title":"Liquid biopsy: comprehensive overview of circulating tumor DNA (review)","volume":"28","author":"Ge","year":"2024","journal-title":"Oncol Lett"},{"key":"2026101309215473900_vdag253-B57","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/jnci\/88.20.1456","article-title":"Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers","volume":"88","author":"Hayes","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"2026101309215473900_vdag253-B58","doi-asserted-by":"publisher","first-page":"943253","DOI":"10.3389\/fonc.2022.943253","article-title":"Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis","volume":"12","author":"S\u00e1nchez-Herrero","year":"2022","journal-title":"Front Oncol"},{"key":"2026101309215473900_vdag253-B59","doi-asserted-by":"publisher","first-page":"ii22","DOI":"10.1093\/noajnl\/vdac021","article-title":"Noninvasive approaches to detect methylation-based markers to monitor gliomas","volume":"4","author":"Noushmehr","year":"2022","journal-title":"Neurooncol Adv"},{"key":"2026101309215473900_vdag253-B60","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-020-0932-2","article-title":"Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes","volume":"26","author":"Nassiri","year":"2020","journal-title":"Nat Med"},{"key":"2026101309215473900_vdag253-B61","doi-asserted-by":"publisher","first-page":"100926","DOI":"10.1016\/j.medj.2025.100926","article-title":"The comings and goings of cell-free DNA: biological and clinical implications","volume":"7","author":"Malki","year":"2026","journal-title":"Med"},{"key":"2026101309215473900_vdag253-B62","doi-asserted-by":"publisher","first-page":"9650","DOI":"10.1038\/s41598-018-27368-3","article-title":"Evaluation of droplet digital PCR and next generation sequencing for characterizing DNA reference material for KRAS mutation detection","volume":"8","author":"Dong","year":"2018","journal-title":"Sci Rep"},{"key":"2026101309215473900_vdag253-B63","doi-asserted-by":"publisher","first-page":"100480","DOI":"10.1016\/j.jlb.2026.100480","article-title":"Molecular sampling limits of ctDNA detection in clinical plasma samples","volume":"13","author":"Gamisch","year":"2026","journal-title":"J Liq Biopsy"},{"key":"2026101309215473900_vdag253-B64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14737159.2018.1400384","article-title":"Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective","volume":"18","author":"Postel","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"2026101309215473900_vdag253-B65","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1093\/neuonc\/noad164","article-title":"H3K27M mutant glioma: disease definition and biological underpinnings","volume":"26","author":"Saratsis","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026101309215473900_vdag253-B66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25053040","article-title":"Glioblastoma: an update in pathology, molecular mechanisms and biomarkers","volume":"25","author":"Lan","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026101309215473900_vdag253-B67","doi-asserted-by":"publisher","first-page":"eaat4921","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026101309215473900_vdag253-B68","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1227\/neu.0000000000003929","article-title":"Molecular features of glioblastoma isocitrate dehydrogenase-wildtype in extreme survival groups after supramaximal and maximal resection","volume":"99","author":"Bueno","year":"2026","journal-title":"Neurosurgery."},{"key":"2026101309215473900_vdag253-B69","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1227\/neu.0000000000001982","article-title":"Circulating tumor DNA in adults with glioma: a systematic review and meta-analysis of biomarker performance","volume":"91","author":"McMahon","year":"2022","journal-title":"Neurosurgery"},{"key":"2026101309215473900_vdag253-B70","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyag228","article-title":"Clinical and molecular response to vorasidenib in post-transplant patient with IDH2-mutant intrahepatic cholangiocarcinoma","volume":"31","author":"Altiery De Jesus","year":"2026","journal-title":"Oncologist"},{"key":"2026101309215473900_vdag253-B71","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1038\/s41598-021-84513-1","article-title":"Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR","volume":"11","author":"Li","year":"2021","journal-title":"Sci Rep"},{"key":"2026101309215473900_vdag253-B72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jocn.2020.10.005","article-title":"Adult diffuse midline gliomas: clinical, radiological, and genetic characteristics","volume":"82","author":"Dono","year":"2020","journal-title":"J Clin Neurosci"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag253\/71322765\/vdag253.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag253\/71322765\/vdag253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag253\/71322765\/vdag253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:22:01Z","timestamp":1791897721000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag253\/8829376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag253","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag253"}}